Recurrent YAP1-TFE3 Gene Fusions in Clear Cell Stromal Tumor of the Lung

. 2021 Nov 01 ; 45 (11) : 1541-1549.

Jazyk angličtina Země Spojené státy americké Médium print

Typ dokumentu kazuistiky, časopisecké články, Research Support, N.I.H., Extramural, práce podpořená grantem

Perzistentní odkaz   https://www.medvik.cz/link/pmid33899786

Grantová podpora
P30 CA008748 NCI NIH HHS - United States
P50 CA140146 NCI NIH HHS - United States
P50 CA217694 NCI NIH HHS - United States

Odkazy

PubMed 33899786
PubMed Central PMC8516668
DOI 10.1097/pas.0000000000001719
PII: 00000478-202111000-00011
Knihovny.cz E-zdroje

Clear cell (hemangioblastoma-like) stromal tumor of the lung (CCST-L) is a recently described distinctive rare pulmonary neoplasm of unknown histogenesis and molecular pathogenesis. Only 7 cases have been reported in 2 recent studies, although additional cases might have been reported under the heading of extraneural pulmonary hemangioblastoma. We herein describe 4 CCST-L cases, 3 of them harboring a YAP1-TFE3 fusion. The fusion-positive tumors occurred in 3 women, aged 29, 56, and 69 years. All presented with solitary lung nodules measuring 2.3 to 9.5 cm. Histologically, all tumors showed similar features being composed of relatively uniform medium-sized epithelioid to ovoid cells with clear cytoplasm and small round monomorphic nuclei. Scattered larger cells with enlarged hyperchromatic nuclei and marked pleomorphism were noted in 2 cases. The tumors were associated with a hypervascularized stroma with variable but essentially subtle resemblance to capillary hemangioblastoma and perivascular epithelioid cell tumor (PEComa). Immunohistochemistry was negative for all lineage-specific markers. Targeted RNA sequencing showed a YAP1-TFE3 fusion in 3 of 4 cases. All 3 tumors showed homogeneous nuclear TFE3 immunoreactivity. Two patients were disease free at 36 and 12 months. The third patient had biopsy-proven synchronous renal and hepatic metastases, but extended follow-up is not available (recent case). The fourth case lacking the fusion affected a 66-year-old woman and showed subtle histologic differences from the fusion-positive cases, but had comparable TFE3 immunoreactivity. CCST-L represents a distinctive entity unrelated to hemangioblastoma and likely driven by recurrent YAP1-TFE3 fusions in most cases. The relationship of our cases to the recently reported "hemangioblastoma-like" CCST-L remains to be determined. Analysis of larger series is paramount to delineate the morphologic spectrum and biological behavior of this poorly characterized entity.

Zobrazit více v PubMed

Bisceglia M, Muscarella LA, Galliani CA, Zidar N, Ben-Dor D, Pasquinelli G, la Torre A, Sparaneo A, Fanburg-Smith JC, Lamovec J, Michal M, Bacchi CE. Extraneuraxial Hemangioblastoma: Clinicopathologic Features and Review of the Literature. Adv Anat Pathol. 2018;25:197–215. PubMed

Michal M, Vanecek T, Sima R, et al. Primary capillary hemangioblastoma of peripheral soft tissues. Am J Surg Pathol. 2004;28:962–966. PubMed

Doyle LA, Fletcher CD. Peripheral hemangioblastoma: clinicopathologic characterization in a series of 22 cases. Am J Surg Pathol 2014;38:119–27. PubMed

Abbott KH, Love JG. Metastasizing intracranial tumors. Ann Surg. 1943;118:343–352. PubMed PMC

Lindholm KE, Moran CA. Hemangioblastoma-like Clear Cell Stromal Tumor of the Lung: A Clinicopathologic and Immunohistochemical Study of 5 Cases. Am J Surg Pathol. 2020;44:771–775. PubMed

Falconieri G, Mirra M, Michal M, Suster S. Hemangioblastoma-like clear cell stromal tumor of the lung. Adv Anat Pathol 2013;20:130–5. PubMed

Robinson JT, Thorvaldsdóttir H, Winckler W, Guttman M, Lander ES, Getz G, Mesirov JP. Integrative Genomics Viewer. Nature Biotechnology 2011;29:24–26. PubMed PMC

Zheng Z, Liebers M, Zhelyazkova B, Cao Y, Panditi D, Lynch KD, Chen J, Robinson HE, Shim HS, Chmielecki J, Pao W, Engelman JA, Iafrate AJ, Le LP. Anchored multiplex PCR for targeted next-generation sequencing. Nat Med. 2014;20:1479–84. PubMed

Zhu G, Benayed R, Ho C, Mullaney K, Sukhadia P, Rios K, Berry R, Rubin BP, Nafa K, Wang L, Klimstra DS, Ladanyi M, Hameed MR. Diagnosis of known sarcoma fusions and novel fusion partners by targeted RNA sequencing with identification of a recurrent ACTB-FOSB fusion in pseudomyogenic hemangioendothelioma. Mod Pathol. 2019;32:609–620. PubMed PMC

Antonescu CR, Le Loarer F, Mosquera JM, Sboner A, Zhang L, Chen CL, Chen HW, Pathan N, Krausz T, Dickson BC, Weinreb I, Rubin MA, Hameed M, Fletcher CD. Novel YAP1-TFE3 fusion defines a distinct subset of epithelioid hemangioendothelioma. Genes Chromosomes Cancer. 2013;52:775–84. PubMed PMC

Muscarella LA, Bisceglia M, Galliani CA, Zidar N, Ben-Dor DJ, Pasquinelli G, la Torre A, Sparaneo A, Fanburg-Smith JC, Lamovec J, Michal M, Bacchi CE. Extraneuraxial hemangioblastoma: A clinicopathologic study of 10 cases with molecular analysis of the VHL gene. Pathol Res Pract. 2018;214:1156–1165. PubMed

Segawa K, Sugita S, Aoyama T, Minami S, Nagashima K, Tsuda M, Tanaka S, Hasegawa T. Detection of VHL deletion by fluorescence in situ hybridization in extraneuraxial hemangioblastoma of soft tissue. Pathol Int 2020;70:473–475. PubMed

Argani P, Zhong M, Reuter VE, Fallon JT, Epstein JI, Netto GJ, Antonescu CR. TFE3-Fusion Variant Analysis Defines Specific Clinicopathologic Associations Among Xp11 Translocation Cancers. Am J Surg Pathol 2016;40:723–37. PubMed PMC

Dickson BC, Chung CT, Hurlbut DJ, Marrano P, Shago M, Sung YS, Swanson D, Zhang L, Antonescu CR. Genetic diversity in alveolar soft part sarcoma: A subset contain variant fusion genes, highlighting broader molecular kinship with other MiT family tumors. Genes Chromosomes Cancer. 2019. August 21:10.1002/gcc.22803. doi: 10.1002/gcc.22803. PubMed DOI PMC

Argani P, Aulmann S, Illei PB, Netto GJ, Ro J, Cho HY, Dogan S, Ladanyi M, Martignoni G, Goldblum JR, Weiss SW. A distinctive subset of PEComas harbors TFE3 gene fusions. Am J Surg Pathol. 2010;34:1395–406. PubMed

Agaram NP, Sung YS, Zhang L, Chen CL, Chen HW, Singer S, Dickson MA, Berger MF, Antonescu CR. Dichotomy of Genetic Abnormalities in PEComas With Therapeutic Implications. Am J Surg Pathol 2015;39:813–25. PubMed PMC

Rosenbaum E, Jadeja B, Xu B, Zhang L, Agaram NP, Travis W, Singer S, Tap WD, Antonescu CR. Prognostic stratification of clinical and molecular epithelioid hemangioendothelioma subsets. Mod Pathol. 2020;33:591–602. PubMed PMC

Sharain RF, Gown AM, Greipp PT, Folpe AL. Immunohistochemistry for TFE3 lacks specificity and sensitivity in the diagnosis of TFE3-rearranged neoplasms: a comparative, 2-laboratory study. Hum Pathol 2019;87:65–74. PubMed

Flucke U, Vogels RJ, de Saint Aubain Somerhausen N, Creytens DH, Riedl RG, van Gorp JM, Milne AN, Huysentruyt CJ, Verdijk MA, van Asseldonk MM, Suurmeijer AJ, Bras J, Palmedo G, Groenen PJ, Mentzel T. Epithelioid Hemangioendothelioma: clinicopathologic, immunhistochemical, and molecular genetic analysis of 39 cases. Diagn Pathol. 2014;9:131. PubMed PMC

Thway K, Fisher C. PEComa: morphology and genetics of a complex tumor family. Ann Diagn Pathol. 2015;19:359–68. PubMed

Dimmler A, Seitz G, Hohenberger W, Kirchner T, Faller G. Late pulmonary metastasis in uterine PEComa. J Clin Pathol. 2003;56:627–8. PubMed PMC

Caliò A, Mengoli MC, Cavazza A, Rossi G, Ghimenton C, Brunelli M, Pea M, Chilosi M, Marcolini L, Martignoni G. Cathepsin K expression in clear cell "sugar" tumor (PEComa) of the lung. Virchows Arch 2018;473:55–59. PubMed

Zhao M, Rao Q, Wu C, Zhao Z, He X, Ru G. Alveolar soft part sarcoma of lung: report of a unique case with emphasis on diagnostic utility of molecular genetic analysis for TFE3 gene rearrangement and immunohistochemistry for TFE3 antigen expression. Diagn Pathol. 2015;10:160. PubMed PMC

Najít záznam

Citační ukazatele

Nahrávání dat ...

Možnosti archivace

Nahrávání dat ...